However, approximately 60% of high-risk NB tumors are non-MYCN-amplified [29,30,31]; therefore, these findings may explain this pattern of OS survival in patients with non-amplified tumors, which is consistent with our in silico analysis. Here, MYCN is linked to neuroblastoma.